Présentation de l'entreprise
INmune Bio Inc. (INMB) operates as a clinical-stage immunology company dedicated to developing pharmaceutical agents designed to reprogram the innate immune system for treating diseases within the United States. The enterprise focuses its R&D efforts on product candidates intended for hematologic malignancies, solid tumors, and chronic inflammation. This biotechnology firm functions within the broader Healthcare sector, specifically inside the specialized Biotechnology industry, which typically involves high capital expenditure and long development cycles before commercialization. The company currently maintains a market capitalization of $34.29M, generates annual revenue of $50,000, and employs a workforce of 21 individuals. These financial metrics indicate that INmune Bio is a micro-cap entity with negligible current revenue generation relative to its market valuation, reflecting its status as a pre-commercial asset where value is derived primarily from intellectual property potential rather than operational earnings. The disparity between its $34.29M market cap and its minimal revenue suggests the market is pricing the company based on future clinical trial outcomes and regulatory approval probabilities rather than current cash flow performance.
Santé financière
The company reported revenue of $50,000 over the trailing twelve months, yet it posted a net income of $-45,933,000 and an EBITDA of $-30,785,000. The substantial gap between the minimal revenue of $50,000 and the net loss of $-45,933,000 reveals a cost structure heavily dominated by research and development expenses, administrative overhead, and likely clinical trial costs rather than cost of goods sold. Free cash flow stands at $-13,025,125, indicating that the company is burning cash to fund its operations and development pipeline without generating sufficient operating cash to cover its expenditures. The gross margin is reported at 100.0%, a metric common in early-stage biotechnology where revenue is minimal and costs are largely fixed R&D investments not allocated against sales in the traditional sense. However, the operating margin is -61738.0% and the profit margin is 0.0%, figures that reflect the extreme dilution of earnings by non-operational losses and the absence of scalable revenue to absorb fixed costs. The balance sheet holds $24.75M in cash against $1.03M in debt, resulting in a debt-to-equity ratio of 4.40, which presents a leveraged profile typical for cash-rich but loss-making biotech firms where equity is often diluted to raise capital. The current ratio is 3.55, suggesting strong short-term liquidity as the company holds significantly more current assets than current liabilities, providing a buffer against its cash burn rate. Return on Equity is -165.2% and Return on Assets is -53.7%, metrics that indicate management is currently unable to generate positive returns on the capital invested in the firm due to the heavy investment phase inherent in clinical-stage development.
Évaluation de la valorisation
INmune Bio Inc. exhibits a P/E Ratio (TTM) of N/A due to its negative earnings, while the Forward P/E is listed at -1.65, a valuation metric that is not meaningful for a company with no positive earnings trajectory and implies that traditional earnings-based valuation models are inapplicable at this stage. The price-to-book ratio stands at 1.46, indicating that the market values the company at 46% above its tangible book value, a premium often granted to firms with valuable intangible assets such as patent portfolios and proprietary drug candidates. The price-to-sales ratio is exceptionally high at 685.90, and the EV/EBITDA is -0.34, both alternative metrics suggesting that the stock price is detached from current operational performance and relies entirely on speculative future growth expectations. The 52-week high is $11.64 and the 52-week low is $1.09, providing a historical trading range that illustrates significant volatility within the biotechnology sector. Without a specific current share price provided in the facts to calculate the exact percentage, the trading range itself demonstrates the asset's sensitivity to clinical data releases and broader market sentiment regarding immunology therapies. The beta value is 0.89, which indicates that the stock's price volatility is slightly lower than the broader market benchmark, suggesting it may be less reactive to general market swings than high-beta small-cap biotechnology peers, although this does not guarantee lower risk given the binary nature of drug development.
Growth & Income
The revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, as the company lacks the historical revenue data required to calculate year-over-year percentage changes or meaningful earnings growth rates. Consequently, it is impossible to determine whether earnings are growing faster or slower than revenue because the company has not yet achieved profitability or consistent revenue streams to establish a growth baseline. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, which is listed as 0.0%, reflecting a capital allocation strategy focused on reinvesting all available cash into research, development, and clinical trials rather than returning capital to shareholders. This approach is standard for clinical-stage immunology companies that must prioritize funding their pipeline to achieve regulatory approval and commercial viability before initiating any dividend payments. The overall growth and income profile is characterized by a complete absence of historical income generation and dividend distribution, relying instead on the potential for future commercialization of its product candidates to drive shareholder value.